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Background: Premature rupture of the membranes (PROM) is most commonly diagnosed using physical examination;
however, accurate decision making in ambiguous cases is a major challenge in current obstetric practice. As this may
influence a woman’s subsequent management, a number of tests designed to assist with confirming a diagnosis of
PROM are commercially available. This study sought to evaluate the published data for the accuracy of two amniotic
fluid-specific biomarker tests for PROM: insulin-like growth factor binding protein-1 (IGFBP-1 – Actim® PROM) and
placental alpha microglobulin-1 (PAMG-1 – AmniSure®).
Methods: Main analysis included all PubMed referenced studies related to Actim® PROM and AmniSure® with available
data to extract performance rates. To compare accuracy, a comparison of pooled indexes of both rapid tests was
performed. Studies in which both tests were used in the same clinical population were also analysed. Membrane
status, whether it was known or a suspected rupture, and inclusion or not of women with bleeding, were considered.
Results: All the available studies published in PubMed up to April 2013 were reviewed. Data were retrieved from 17
studies; 10 for Actim® PROM (n = 1066), four for AmniSure® (n = 1081) and three studies in which both biomarker tests
were compared directly. The pooled analysis found that the specificity and positive predictive value were significantly
higher for AmniSure® compared with Actim® PROM. However, when 762 and 1385 women with known or suspected
rupture of membranes, respectively, were evaluated, AmniSure® only remained significantly superior in the latter group.
Furthermore, when the two tests were compared directly in the same study no statistically significant differences were
observed. Remarkably, women with a history or evidence of bleeding were excluded in all four studies for AmniSure®,
in two Actim® PROM studies and in two of the three studies reporting on both tests.
Conclusions: No differences were observed in the performance of the two tests in studies where they were used
under the same clinical conditions or in women with known membrane status. Although AmniSure® performed better
in suspected cases of PROM, this may need further analysis as exclusion of bleeding may not be representative of the
real clinical presentation of women with suspected PROM.
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Disruption of foetal membranes prior to the onset of
labour, commonly known as premature rupture of mem-
branes (PROM), is a frequent complication of pregnancy
[1,2]. PROM occurs in 8 − 10% of all pregnancies [3] and
pre-term PROM (PROM <37 weeks’ gestation) is associated
with approximately a third of all premature births [1,2].
Often considered as an inert gestational sac, foetal mem-
branes have a stratified structure with special biochemical
characteristics that provide them with the ability to adapt
to the expansion that occurs during pregnancy, resulting
from increasing foetal size and amniotic fluid. Foetal mem-
branes are composed of two layers, the amnion which faces
the amniotic cavity and the chorion which faces the decidua
[4]. Membrane integrity is essential to ensure normal term
pregnancy. Evidence suggests that the mechanisms involved
in the rupture of membranes include biochemical, im-
munologic and bacteriologic events. Currently, it is widely
accepted that term or preterm rupture is associated with
structural changes, caused by inflammatory processes
induced by endocrine or infectious triggers [5,6].
The main complications and consequences of PROM
are related to the gestational age at which it occurs, the
latency until birth, concomitant infection of the gestational
tissues which may impact both foetal and maternal out-
comes, in addition to conditions specific to the foetus, such
as oligohydramnios, cord compression, abruptio or cord
prolapse [2]. The accurate diagnosis of PROM coupled with
appropriate obstetric interventions, according to gestational
age, are of key importance to limit the potential risk posed
by these adverse maternal and foetal outcomes.
Without clear evidence of amniotic fluid loss observed
by speculum examination, the diagnosis of PROM can
be uncertain and complementary diagnostic tests are
frequently needed. The diagnostic confirmation in am-
biguous cases is a major challenge in current obstetric
practice, because correct diagnosis is necessary in order
to decide upon the most appropriate management and
ultimately to reduce both maternal and foetal complica-
tions. The optimal test should be specific for amniotic
fluid and not be affected by contamination from other
corporal substances or vaginal medications. Multiple
tests with varying performance, are available in order to
assess the integrity of foetal membranes [7,8], including
cytological, biochemical, or colorimetric and ultrasound
techniques. Limitations of the accuracy of tests, e.g. poor
specificity (i.e. a high proportion of false positives), may
lead to unnecessary interventions such as hospitalisation,
antibiotic therapy, application of corticosteroids [9,10] and
even induction of labour [3,9,10]. In contrast, poor sensi-
tivity (i.e. a high proportion of false negative results) may
be reassuring and delay or deprive women of appropriate
treatments [2], increasing the risk of potential maternal
and foetal morbidity and mortality. Traditional bedsideand non-invasive tests, such as the fern and nitrazine test,
have a high rate of false-negative and false-positive results
in cases where women have vaginal infections or the pres-
ence of semen, blood or topical antiseptics [1,3].
New non-invasive tests have been developed in the last
15–20 years, with a simple dipstick test format, based
on the detection of specific proteins found in amniotic
fluid and which combine high sensitivity rates with low
false-positive results. There are a number of rapid immuno-
assay tests commercially available, of which the most
commonly used are Actim® PROM (Medix Biochemica,
Kauniainen, Finland), designed to detect insulin-like growth
factor-binding protein-1 (IGFBP-1), and AmniSure® (Qiagen,
Hilden, Germany) which detects the presence of placental
alpha macroglobulin-1 (PAMG-1).
IGFBP-1 is an excreted protein synthesised in the
decidual cells and foetal liver and detected in amniotic
fluid throughout pregnancy [11-14]. Although serum
concentration of IGFBP-1 increases with gestational age
[12], it is found at considerably lower concentrations in
maternal serum compared to amniotic fluid. This con-
centration difference is also described for PAMG-1 [14],
although reported concentration data vary between publi-
cations [15]. Biomarker and rapid test characteristics
are shown in Table 1. Samples for both tests are collected
with a sterile polyester swab before vaginal examination
and/or vaginal ultrasound. The sample is collected from
vaginal fluid and extracted by placing the swab in a buffer
containing a solvent, with the lower end of the strip
submerged.
The aim of this study was to compare the available
information on two of the most commonly used com-
mercially available rapid tests for the diagnosis of PROM.
This study sought not only to critically evaluate the pub-
lished evidence on the use of IGFBP-1 (Actim® PROM)
and PAMG-1 (AmniSure®) tests and make a comparison
of their performance indices (sensitivity, specificity, posi-
tive predictive value [PPV] and negative predictive value
[NPV]) for the diagnosis of PROM, but also to identify
any variants that may influence the reported performance
of both tests. These variants included the diagnosis status
groups (known membrane status and suspected mem-
brane rupture) at the time of inclusion of patients in the
study and the inclusion/exclusion of women with evidence
of bleeding. For this meta-analysis, pooled sensitivity and
specificity rates were calculated based on the results of
those studies which directly compared both tests in the
same clinical setting. The results of this meta-analysis are
of potential value to physicians to help them in their
choice of rapid test to aid in the diagnosis of PROM.
Methods
This analysis was conducted in accordance with PRISMA
(Preferred Reporting Items for Systematic Reviews and
Table 1 Biomarker and rapid test characteristics
Biomarker Biomarker concentrations in bodily fluids Rapid test characteristics
Maternal blood Amniotic fluid Threshold Time to obtain results
Actim® PROM IGFBP-1 29–300 μg/L [12,14] 10,500–350,000 μg/L [12,14] >25 μg/L [12,14] <5 minutes, if positive
At 5 minutes, if negative
AmniSure® PAMG-1 2.5–12.5 ng/ml* 2,000–25,000 ng/ml* >5 ng/ml* 10 minutes after sampling
False results after 15 minutes
*Unpublished values stated in the AmniSure® manufacturer’s instructions for use and information material
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pleted PRISMA 2009 checklist).
A search of the PubMed database was conducted to
identify all published studies, up to April 2013, relating
to the rapid tests Actim® PROM and AmniSure®, without
language restrictions and using a combination of the
predefined search terms: PAMG-1 test, IGFBP-1 test,
PAMG-1 PROM test, IGFBP-1 PROM test, placental
alpha microglobulin-1 PROM test, insulin-like factor
binding protein-1 PROM test, AmniSure® and Actim®
PROM.
All abstracts, full texts and citations were reviewed
to select the papers in which: a) the rapid tests were
used as a tool to diagnose or complement diagnosis of
a rupture of membranes in a clinical setting, where b)
the confirmation on the final membrane status through a
reference method was available in the paper and where c)
the results of the test performance, through sensitivity and
specificity or the raw number of positive and negative test
results, were available. All articles which were not consist-
ent with these criteria were excluded from this analysis.
Data extracted from each study included: year of pub-
lication, inclusion and exclusion criteria of the study (e.g.
active bleeding), gestational age at test performance
(range), number of women excluded and rationale for
exclusion, reference method used to confirm PROM,
condition of women at the beginning of the study (total
women with suspected and confirmed or non-confirmed
PROM), rapid test results and diagnosis (ruptured mem-
branes or intact membranes) at final evaluation. When
values of true positive (TP), false negative (FN), true
negative (TN) and false positive (FP), were not explicitly
reported, these were estimated based on sensitivity and
specificity values and confidence intervals reported in the
original publications.
To provide an estimation of the predictive performance
of the tests, the sensitivity, specificity, PPV and NPV
results for each study were calculated according to the
Newcombe efficient-score method (corrected for con-
tinuity) [16], taking into account only the number of
women with confirmed diagnosis of rupture according
to the reference method in each study (per protocol,
cases of suspected PROM without later confirmation
of the diagnosis were not included in the final analysis).
To further explore the results of this pooled analysis, apost-hoc comparison along with 95% Confidence Intervals
(CIs) was also performed using the chi-square test,
between each test result for subgroups whose membrane
status was known and those who had a suspected mem-
brane rupture, in order to explore reasons for potential
differences. In this comparison, known membrane status
refers to those women for whom membrane integrity sta-
tus was clearly defined, i.e. women without any symptoms
or suspicion of PROM and women who had an artificial
rupture. Suspected membrane rupture refers to women
whose membrane status was not known upon study entry
and who were being evaluated for a suspected rupture. All
probability values were 2-tailed and were corrected for
multiple testing, and p ≤ 0.05 was considered statistically
significant. All the statistical analyses were performed
using Excel 2007 and SPSS 19.0 for Windows.
The results are presented for each test considering
the pooled data and then stratified according to whether
the membrane status was known (intact or ruptured) or
PROM was clinically suspected.
Results
From an initial 125 identified manuscripts, all the retrieved
titles and abstracts were screened to discard repeated
articles, leading to a total of 52 evaluable papers: 31
papers relating to Actim® PROM, 11 papers relating to
AmniSure®, and 10 referring to both biomarkers. After
a detailed process of selection (Figure 1), 35 papers were
excluded because: they did not evaluate the specific bio-
markers as a rapid test for PROM diagnosis [14,17-19],
they studied the concentration of the biomarkers through
pregnancy [11,20-23] or after an amniocentesis [24], they
were solely studies of biochemical processes [25,26], they
were adjunct to a genetic study [27], they comprised
guidelines [9], they were review articles [8,13,28,29], they
were a meta-analysis [30] or letter/comments on other
articles [15,31-33], and they related to the application of
the biomarker in obstetrics [18,23]. In two cases, the full
text version of the studies were not available for consult-
ation [34,35]. The rest of excluded publications: did not
evaluate the commercially available test in a daily clinical
setting (i.e. they were in vitro studies [36-38], or presented
test results mixed with other test modalities [39], they
evaluated physicians’ confidence on PROM suspicion after
the test [40], they presented incomplete data on sensitivity
Figure 1 Flow chart of the selection process.
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method to confirm PROM diagnosis [42,44]). One study
on AmniSure® [45] had been retracted from publication
due to inaccurate results, and thus it was also excluded
from the analysis. Reasons for exclusion and a detailed
flow chart of the selection process are presented in
Figure 1.
Following this screening, data from a total of 17 selected
publications were retrieved for analysis: 10 for Actim®
PROM [12,46-54], four studies for AmniSure® [55-58],
and three studies which evaluated both tests [59-61]. A
complete description of the evaluated trials, including
total samples and exclusion rationales is presented in
Table 2. There were differences between the studies relat-
ing to the methods applied to confirm the diagnosis after
the test had been performed (i.e. different concept of gold
standard). Inclusion criteria for all studies were similar,
except in two evaluating Actim® PROM [50,54], four
studies evaluating AmniSure® [55-58], and two studies
evaluating both tests [59,61], in which women with a
history of bleeding or active bleeding at the time of
evaluation were systematically excluded.
The pooled population consisted of 1066 pregnant
women tested with IGFBP-1 and 1081 tested with
PAMG-1. Prevalence of PROM as a final diagnosis was
approximately 50% for both tests.
Performance indices calculated with the estimated pooled
data of Actim® PROM (TP = 478, FN = 23, TN = 525,
FP = 40) and AmniSure® (TP = 530, FN = 18, TN = 524,
FP = 9) showed no statistical differences regarding sen-
sitivity (Actim® PROM: 95.4% [95% CI = 93.1–97.0] vs.
AmniSure®: 96.7% [95% CI = 94.8–98.0]; p = 0.352) andNPV (Actim® PROM: 95.8% [95% CI = 93.7–97.3] vs.
AmniSure®: 96.7% [95% CI = 94.7–98.0]; p = 0.548). How-
ever, AmniSure® was associated with a higher specifi-
city (98.3% [95% CI = 96.7–99.2]) and PPV (98.3 [95%
CI = 96.7–99.2]) compared with Actim® PROM (speci-
ficity = 92.9% [95% CI = 90.4–94.8]; PPV = 92.3% [95%
CI = 89.5–94.4]; both p < 0.001 vs. AmniSure®).
Following the differences observed between the two
tests in the pooled analysis, a post-hoc analysis of sub-
groups was undertaken to explore the potential reasons
for these differences. Women included in the identified
published studies were a mixed population and most
studies included two types of patients. 1) Women with a
confirmed membrane rupture or intact membranes; in
these studies the women were used to evaluate the tests
as true positive or true negatives, to show the efficacy of
the tests in women with known membrane status. 2)
Women who were suspected of having a membrane rup-
ture; these represent the women who are relevant in the
clinical utility of these tests and studies on these women
evaluated the efficacy of the tests in the clinical setting.
The overall population was stratified into women with
known (Table 3) or suspected rupture of membranes
(Table 4), where 762 and 1385 women, respectively, were
evaluated. In this case, specificity and PPV only remained
significantly higher for AmniSure® in the population where
rupture of membranes was suspected. There were no dif-
ferences between the two tests when they were compared
in the group of women with known membrane status. A
comparison of the performance indices in both popula-
tions is shown in Figure 2. Furthermore, in three studies,
the two tests were compared directly in the same
Table 2 Descriptive data of studies included in the meta-analysis
Reference GA range N (ITT) Women excluded
from reference
analysis
Rationale for
exclusion from
reference analysis
Exclusion of
women with
history or
active bleeding
Reference method N
(PP)
Women excluded
from meta-analysis
Rationale for
exclusion of women
from meta-analysis
Actim® PROM (IGFBP-1)
Rutanen
1996 [12]
15–37 311 0 – No For women with suspected ROM
but equivocal diagnosis, ROM was
assessed based on the interval
between sampling and delivery.
130 181 Women with
suspected ROM but
inadequate reference
method to confirm
PROM.
Ragosch
1996 [50]
22-41 75 0 – Yes Clinical confirmation in cases of
obvious PROM. Women with
unconfirmed PROM underwent
amniocentesis (if patient consented).
75 0
Gaucherand
1997 [53]
19-41 100 0 – No Clinical course and similarity of the
majority of the three tests: Actim®
PROM, DAO and pH.
69 31 Women with
suspected ROM and
PROM confirmation
absent.
Jain 1998 [49] 24-42 100 0 – No Pooling of liquid in the posterior
fornix or seen leaking from the cervix.
100 0 –
Kubota
1998 [46]
15-41 48 0 – No At delivery and/or by observing
the subsequent clinical course.
48 –
Darj 1998 [51] 25-42 174 0 – No Delivery within 48 hours. Method
not available for women with
suspected PROM.
75 99 Women with
suspected ROM but
inadequate reference
method to confirm
PROM.
Guibourdenche
1999 [48]
18-41 80 0 – No For women with suspected PROM,
diagnosis was confirmed using
detection of diamine oxidase in
vaginal secretions (detected by
semi-quantitative radio-enzymatic assay).
30 50 Women with
suspected ROM and
PROM confirmation
absent.
Erdermoglu
2004 [47]
20-42 151 0 – No Speculum examination at inclusion.
Later diagnosis in suspected women
was associated with delivery within
the next 7 days following the test.
71 80 Women with
suspected ROM but
PROM confirmation
absent.
Akercan
2005 [54]
20-36 87 6 Lost on follow-up
(4) and 2 who
refused hospital
admission.
Yes Ongoing vaginal fluid leakage and/or
ruptured amniotic membranes at first
vaginal examination. Pooling of
amniotic fluid in the posterior fornix.
45 36 Women with
suspected ROM but
inadequate reference
method to confirm
PROM.
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Table 2 Descriptive data of studies included in the meta-analysis (Continued)
Martinez de
Tejada 2006 [52]
24-41 83 0 – No Presence of AF in the vagina or total
absence of vaginal secretions, alkaline
pH, positive fern test, oligohydramnios
(AFI <5 cm), chorioamnionitis, absence
or very little amount of AF leakage
during labour and delivery.
83 0 –
Tagore
2010 [59]
17-37 100 6 Not specified
on paper.
Yes Three or more of: definite pooling of
clear fluid during speculum examination,
oligohydramnios on ultrasound, signs
and symptoms of chorioamnionitis and
preterm delivery within a week of
presentation along with convincing
history of leaking liquor.
94 0 –
Albayrak
2011 [61]
16-41 179 12 Lost on follow-up. Yes Speculum examination (clear fluid leakage
and two of: sonographic AFI, Fern, pH. Furth
dx was confirmed based on the duration o
latency period, results of repeat speculum
examinations, repeat ferning, nitrazine and
strip tests and decrease of AFI, and clinica
signs of foetal distress or chorioamnionitis
167 0 –
Marcellin
2011 [60]
Not
specified
80 1 Patient from the
PROM group with
placenta previa.
Not specified Evident liquid outlet at vaginal examinatio 79 0 –
AmniSure® (PAMG-1)
Cousins
2005 [55]
15-42 203 0 – Yes Two of: visual pooling of AF,
alkaline pH, positive Fern test.
203 0 –
Lee SE
2007 [56]
11-42 184 1 Lost on follow-up. Yes Leaking from the cervical OS on speculum
examination or two of: visual pooling of flu
in the posterior fornix, positive nitrazine te
or positive fern test.
183 0 –
Tagore
2010 [59]
17-37 100 0 – Yes Three or more of: definite pooling of
clear fluid during speculum examination
oligohydramnios on ultrasound, signs
and symptoms of chorioamnionitis and
preterm delivery within a week of
presentation along with convincing
history of leaking liquor.
100 0 –
Marcellin
2011 [60]
Not
specified
80 1 Patient from the
PROM group with
placenta previa.
Not specified Evident liquid outlet at vaginal examination 79 0 –
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Table 2 Descriptive data of studies included in the meta-analysis (Continued)
Albayrak
2011 [61]
16-41 179 12 Lost on follow-up. Yes Speculum examination (clear fluid
leakage) and two of: sonographic AFI,
Fern, pH. Further diagnosis was confirmed
based on the duration of latency period,
results of repeat speculum examinations,
repeat ferning, nitrazine and strip tests and
decrease of AFI, and clinical signs of foetal
distress or chorioamnionitis.
167 0 –
Birkenmaier
2012 [57]
17-42 202 3 Excluded
retrospectively due
to incomplete
medical records.
Yes Two of: visual leaking or
pooling of AF from the
cervix on the speculum examination,
positive nitrazine test or AFI <5 cm
in the ultrasound examination.
Definitive dx was diagnosed
on review of medical records
when there was documented
evidence of intact or ruptured
membranes with consecutive
loss of fluid during delivery.
199 0 –
Abdelazim
2012 [58]
>37 150 0 – Yes History of sudden gush of water,
pooling of AF, positive ferning
pattern, positive nitrazine test and
confirmed by visualisation of fluid
passing from the cervical canal
during sterile speculum examination.
150 0 –
AF: Amniotic fluid; AFI: Amniotic fluid index; GA: Gestational age in weeks; ITT: Intention to Treat; PP: Per Protocol; DAO: Diamine oxidase.
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Table 3 Summary of study results for women with known membrane status; women included in studies who had a
confirmed membrane rupture or intact membranes (not suspected of PROM) upon entry to the study
Study N TP FN TN FP Sensitivity% (CI) Specificity% (CI) PPV% (CI) NPV% (CI)
Marcellin 2011 [60] 79 39 1 38 1 97.5 (85.7–100) 97.4 (82.4–99.4) 97.5 (88.5–100) 97.4 (92.5–100)
Martinez de Tejada 2006 [52] 34 20 0 13 1 100 (79.9–100) 92.8 (64.2–99.6) 95.2 (74.1–99.7) 100 (71.7–100)
Akercan 2005 [54] 45 25 0 19 1 100 (83.4–100) 95.0 (73.1–99.7) 96.1 (78.4–99.8) 100 (79.1–100)
Erdermoglu 2004 [47] 71 35 1 34 1 97.2 (83.8–99.8) 97.1 (83.4–99.8) 97.2 (83.8–99.8) 97.1 (83.4–99,8)
Darj 1998 [51] 75 44 2 27 2 95.6 (84.0–99.2) 93.1 (75.8–98.8) 95.7 (84.0–99.2) 93.1 (75.8–98.8)
Gaucherand 1997 [53] 69 34 1 34 0 97.1 (83.4–99.8) 100 (87.4–99.8) 100 (87.4–100) 97.1 (83.4–99.8)
Guibourdenche 1999 [48] 30 15 0 14 1 100 (74.6–100) 93.3 (66.0–99.7) 93.8 (67.7–99.7) 100 (73.2–100)
Rutanen 1996 [12] 130 55 0 71 4 100 (91.9–100) 94.7 (86.2–98.3) 93.2 (82.7–97.8) 100 (93.6–100)
Actim PROM® pooled 533 267 5 250 11 98.2 (95.5–99.3) 95.8 (92.4–97.8) 96.0 (92.8–97.9) 98.0 (95.2–99.3)
Abdelazim 2012 [58] 150 73 2 74 1 97.3 (89.8–99.5) 98.7 (91.8–99.9) 98.6 (91.7–99.9) 97.4 (90.0–99.5)
Marcellin 2011 [60] 79 38 2 38 1 95.0 (82.4–99.4) 94.8 (79.3–98.0) 95.0 (84.7–100) 94.8 (87.9–100)
AmniSure® pooled 229 111 4 112 2 96.5 (90.8–98.9) 98.2 (93.2–99.7) 98.2 (93.1–99.7) 96.5 (90.9–98.9)
CI: Confidence Interval; TP: True Positives; FN: False Negatives; TN: True Negatives; FP: False Positives.
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nificant difference in any of the performance metrics of
Actim® PROM compared with AmniSure® (Table 5).
Discussions
Based on clinical evaluation, PROM can be equivocal in
10 to 20% of women consulting due to suspected loss of
vaginal fluid [2,33]. Improved diagnostic methods, using
biochemical markers specific for amniotic fluid, have
been developed and extensively studied in the last few
decades. These biomarkers are found at higher concentra-
tions in amniotic fluid compared with vaginal fluid and
thus provide a strong predictive value for the diagnosis of
PROM. Multiple studies have shown the superiority of the
new generation of tests, which have improved ease ofTable 4 Summary of study results for women with suspected
status upon entry to the study but who had a suspected mem
Study N TP FN TN FP Sensiti
Albayrak 2011 [61] 167 79 9 77 2 89.8 (8
Tagore 2010 [59] 94 35 5 51 3 87.5 (7
Martinez de Tejada 2006 [52] 49 19 3 20 7 86.4 (6
Kubota 1998 [46] 48 18 1 27 2 94.7 (7
Jain 1998 [49] 100 25 0 67 8 100 (8
Ragosch 1996 [50] 75 35 0 33 7 100 (8
Actim® PROM pooled 533 211 18 275 29 92.1 (8
Birkenmaier 2012 [57] 199 51 3 143 2 94.4 (8
Albayrak 2011 [61] 167 83 5 77 2 94.3 (8
Tagore 2010 [59] 100 38 3 59 0 92.7 (7
Lee 2007 [56] 183 157 2 21 3 98.7 (9
Cousins 2005 [55] 203 90 1 112 0 98.9 (9
AmniSure® pooled 852 419 14 412 7 96.8 (9
CI: Confidence Interval; TP: True Positives; FN: False Negatives; TN: True Negatives; Fsample processing and accuracy, compared with ‘classic’
tests [7,47,53].
The main finding of this analysis was the fact that the
two tests evaluated (Actim PROM® and AmniSure®) per-
formed equally when they were compared directly under
the same clinical conditions and where women with
known membranes status were tested. Considering the
estimated pooled data, AmniSure® showed a higher
specificity and PPV than Actim® PROM. As a result of
these differences, the post-hoc analysis of subgroups was
performed to evaluate separately women with known
membrane status from those with suspected rupture of
membranes, finding that a higher specificity and PPV of
AmniSure® was only observed in samples from cases of
suspected rupture of membranes (Figure 2).membrane rupture; women with unknown membrane
brane rupture
vity% (CI) Specificity% (CI) PPV% (CI) NPV% (CI)
1 0–94.9) 97.5 (90.3–99.6) 97.5 (90.5–99.6) 89.5 (80.6–94.8)
2.4–95.3) 94.4 (83.7–98.6) 92.1 (77.5–97.9) 91.1 (79.6–96.7)
4.0–96.4) 74.1 (53.4–88.1) 73.1 (51.9–87.6) 87.0 (65.3–96.6)
1.9–99.7) 93.1 (75.8–98.8) 90.0 (66.9–98.2) 96.4 (79.8–99.8)
3.4–100) 89.3 (79.5–94.9) 75.8 (57.4–88.3) 100 (93.2–100)
7.7–100) 82.5 (66.6–92.1) 83.3 (68.0–92.5) 100 (87.0–100)
7.7–95.1) 90.5 (86.4–93.4) 87.9 (82.9–91.6) 93.9 (90.3–96.2)
3.7–98.6) 98.6 (94.6–99.8) 96.2 (85.9–99.3) 97.9 (93.6–99.5)
6.6–97.9) 97.5 (90.3–99.6) 97.6 (91.0–99.6) 93.9 (85.7–97.7)
9.0–98.1) 100 (92.4–100) 100 (88.6–100) 95.2 (85.6–98.7)
5.1–99.8) 87.5 (66.5–96.7) 98.1 (94.2–99.5) 91.3 (70.5–98.5)
3.2–99.9) 100 (95.9–100) 100 (94.9–100) 99.1 (94.4–99.95)
4.5–98.1) 98.3 (96.4–99.3) 98.4 (96.5–99.3) 96.7 (94.4–98.1)
P: False Positives.
Figure 2 Comparison of the performance indexes in known and suspected PROM populations. *p<0.001. CI: 95% Confidence Interval;
NPV: Negative Predictive Value; PPV: Positive Predictive Value.
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http://www.biomedcentral.com/1471-2393/14/183These observed differences between the two tests could
possibly be linked to the consideration of active or a past
history of bleeding in test evaluations. Six of the seven
AmniSure® studies [55-59,61], explicitly excluded women
when there was evidence of active bleeding, or even aTable 5 Performance in studies with side by side clinical com
Actim® PROM AmniSure®
Sensitivity,% (95% CI)
Marcellin 2011 [60] N = 80 97.5 (85.7–100) 95.0 (82.4–99.4)
Albayrak 2011 [61] N = 167 89.7 (81.0–94.9) 94.3 (86.6–97.9)
Tagore 2010 [59] N =100 87.5 (72.4–95.3) 92.68 (79.0–98.1)
NS: Differences not statistically significant at <0.05. CI: Confidence Interval.history of bleeding. Considering the importance of this
exclusion, we found that eight studies in which women
with bleeding were excluded (four for AmniSure®, two
for Actim® PROM and two for both tests) comprise
more than 90% of the available data relating to womenparison
P Actim® PROM AmniSure® P
Specificity,% (95% CI)
NS 97.4 (82.4–99.4) 94.8 (79.3–98.0) NS
0.768 97.5 (90.3–99.6) 97.5 (90.3–99.6) 1.000
0.480 94.44 (83.7–98.6) 100 (92.4–100) 0.248
Palacio et al. BMC Pregnancy and Childbirth 2014, 14:183 Page 10 of 12
http://www.biomedcentral.com/1471-2393/14/183tested using AmniSure®, but only approximately 20% of
data relating to women tested with Actim® PROM. This
exclusion is most likely due to the reported interference of
blood with the test performance of AmniSure® (according
to manufacturer’s recommendations), leading to false-
positive results. This is unlike Actim® PROM, which is
understood to be efficient in almost all cases, including
women with some bleeding. This is due to a) the cut-off
detection limit for IGFBP-1 in Actim® PROM is >25 μg/L
in the extracted sample, which corresponds to a concen-
tration of >400 μg/L in the sample taken from the woman,
which is well above the level found in maternal blood
(29–300 μg/L) [12] (Table 1) and b) a low affinity of the
antibody used in Actim® PROM for the highly phosphory-
lated form of IGFBP-1 which is predominant in blood
[25]. Thus blood contamination is highly unlikely to affect
the test result of Actim® PROM. Altogether, these data
provide supporting evidence that blood contamination
may have limited impact on Actim® PROM’s performance
[12,46-48]. The presence of blood, in varying degrees, is
observed in up to 20% of PROM cases, it is particularly
common during the pre-labour period due to cervical
ripening [12,46,47] or in cases of placental implantation
abnormalities (i.e. placentae previa).
The exclusion of women with bleeding can consequently
provide unrepresentative performance values of a test for
PROM and may impact upon test accuracy. Indeed, as the
threshold of the AmniSure® test is very close to the lower
limit described as a normal range in the maternal serum
(Table 1), it could be hypothesized that traces of blood
would have resulted in more false-positive tests, thus limit-
ing the specificity, while this threshold is well above the
levels found in maternal blood for the Actim® PROM test.
Therefore, the presence of traces of blood should not im-
pact on the test results using Actim® PROM. In a recently
published meta-analysis that concluded a superiority of the
AmniSure® test compared with the Actim® PROM test
(Ramsauer et al. [62]), this exclusion of women with
contaminating blood in their samples was not consi-
dered. Therefore, the results of this analysis should be
interpreted with caution.
Another strength of the meta-analysis reported here
is that it only included studies which met well-defined
criteria. In the meta-analysis by Ramsauer et al. [62]
comparing the two tests, the criteria for selection of the
studies were in some cases conflicting with the described
methodology: some of the published data available at that
time were not included [58,60] and some evidence on
AmniSure® results could not be verified because it was
published only in abstract form and not available as full
text [41].
It should also be noted that the study for AmniSure®
with the largest sample size [55] was performed with a
version of the test that is no longer commerciallyavailable. Although instructions for use only vary slightly
from the currently available test (the diluent with the sam-
ple was applied to a slide instead of a test strip dipped
directly into the diluent vial), it is not known whether this
new test strip format has any influence on the efficacy of
AmniSure® for the diagnosis of PROM. Of interest is the
fact that the prevalence of the final diagnosis of PROM in
the pooled data is approximately 50%, which depicts the
true nature of the conflicting diagnosis of PROM being
evaluated. This meta-analysis thus reflects the clinical
situation experienced by physicians, in which women
presenting with suspected PROM have a final con-
firmed diagnosis in approximately 50% of cases.
Our results, however, are not exempt from limitations,
mainly related to the high complexity involved in the
evaluation of the performance of diagnostic tests and the
possibility of misleading published studies which are not
available through Medline searches, in addition to the
heterogeneity of design across studies. These factors were
considered and lead us to perform subgroup analysis,
which included those papers in which the final outcome
was an interpretation of the performance index presented
by the authors of each publication.
Particularly when tests are evaluated in the clinical set-
ting, when PROM is suspected, the specific characteristics
of each test, the selection of the women and the reference
method used to confirm the diagnosis may contribute to
inconsistencies. This is due to the fact that in most of the
studies available for consultation, the reference method
was not clearly stated or was heterogeneous (included a
composite reference method, which combined the results
of several available tests [12]).
A number of statistical methods have been proposed to
estimate the performance of tests in the absence of a single
accepted reference standard [13,14]. The importance of the
diagnostic criteria for assessment of the tests performance
is particularly highlighted in the group of suspected cases,
where the sensitivity and specificity rates vary strongly
throughout the studies. These findings suggest that the
women had heterogeneous clinical characteristics and were
managed according to different protocols during the stu-
dies, i.e., regarding reference methods to confirm PROM.
In contrast, prevalence rates as well as accuracy characteris-
tics such as sensitivity, specificity, PPV and NPV from the
analysed data of Actim® PROM and AmniSure® studies are
reasonably homogeneous. Despite a higher number of
published studies for Actim® PROM, the total number of
women included in both rapid test studies is comparable.
Overall, this analysis shows that accuracy of Actim®
PROM and AmniSure® for the detection of PROM are
comparable if used in the same clinical population [59-61].
Although there are significant differences in the test per-
formance in women with suspected membrane rupture,
one should be cautious to conclude from this meta-analysis
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http://www.biomedcentral.com/1471-2393/14/183that under clinical conditions either test is superior in
diagnosing PROM, as women with bleeding were mostly
excluded when testing one of the biomarkers.
Conclusions
In this analysis, both tests appear equally useful for clinical
use to aid in the diagnosis of PROM, as no differences were
observed between the tests when compared side by side in
the same study. The exclusion of women with bleeding
from all but one of the AmniSure® studies may limit direct
comparison of the studies evaluating these two biomarkers.
As some degree of bleeding may be present in a significant
number of women presenting with suspected PROM in
the real clinical setting, further studies are necessary to
consider the performance of AmniSure® in such conditions.
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